Last updated: February 3, 2026
Clinical Trials Status
Insulin Susp Protamine Zinc Purified Pork (IPZ-PP) remains in several phases of clinical development. The product is a long-acting insulin formulation used historically for managing diabetes mellitus type 1 and 2. As of 2023, no new pivotal clinical trials are publicly registered specifically for IPZ-PP. However, researchers and pharmaceutical companies have explored biosimilar variants and bioavailability comparisons.
Key points:
- Phase 3 Trials: The original formulation has completed Phase 3 trials decades ago; ongoing research focuses on biosimilar versions.
- Biosimilar Development: Several companies, notably in emerging markets, develop biosimilars aiming for regulatory approval following successful equivalence studies.
- Regulatory Status: Approved for use in multiple countries, notably in India, South America, and some Southeast Asian markets; no significant recent approvals in the U.S. or Europe.
Market Analysis
Current Market Size and Segments
The global insulin market was valued at approximately USD 27.4 billion in 2022, with a compound annual growth rate (CAGR) forecasted at 8.3% through 2030 [1].
- Insulin Types: Basal insulins like NPH (Neutral Protamine Hagedorn) and its variants, including IPZ-PP, constitute a major segment.
- geografical distribution: Asia-Pacific accounts for around 40% of the market, driven by high diabetes prevalence and low-cost insulin options.
- Product Competition: Modern insulins (analogues) dominate North America and Europe, with biosimilars gaining ground in emerging markets.
Market Drivers
- Increasing diabetes prevalence, with more than 463 million adults affected globally [2].
- Growth in biosimilar adoption as patent protections for original insulins expire.
- Government policies promoting affordable insulin access in low- and middle-income countries.
Market Challenges
- Safety concerns related to animal-derived insulins, including immunogenicity issues.
- Competition from recombinant human insulin and analogs with improved pharmacokinetics.
- Regulatory hurdles limiting approval for animal-source insulins in developed markets.
Competitive Landscape
Key players in insulin biosimilar development, some utilizing pork-derived formulations:
| Company |
Product Name |
Market Focus |
Approval Status |
| Biocon |
Semglee (biosimilar glargine) |
Global |
Approved in US, Europe |
| Wockhardt |
Mitiglinide |
India, Asia |
Approved |
| Laurus Labs |
Insulin Biosimilar |
India |
Pending approval |
The segment involving pork-derived insulin is increasingly niche, with most companies transitioning to recombinant methods due to safety and regulatory reasons.
Projection and Future Outlook
- Market Penetration: Pork-derived insulin formulations like IPZ-PP are expected to decline in markets with strict regulations favoring recombinant versions, but remain relevant in countries where cost is limiting.
- Biosimilar Growth: Biosimilars are anticipated to comprise over 55% of the insulin market by 2030 [1].
- Regulatory Trends: Global trends favor recombinant insulin, yet some regions continue to accept animal-derived products owing to cost advantages or manufacturing constraints.
- Innovations: Long-acting formulations and inhalable insulins are gaining relevance; the role of pork-derived insulin will depend on cost, safety, and regulatory acceptance.
Strategic Recommendations
- For companies with existing pork insulin assets, focus on markets where safety concerns are less restrictive.
- Consider biosimilar development utilizing recombinant technology to expand global reach.
- Engage with regulators early to address safety and immunogenicity concerns in animal-derived insulins.
- Leverage cost advantages in emerging markets by establishing local manufacturing and distribution channels.
Key Takeaways
- The native market for pork-derived insulin formulations like IPZ-PP is shrinking in developed markets due to safety perceptions and regulatory shifts favoring recombinant insulin.
- Biosimilars dominate new market entries, with the overall insulin market growing at approximately 8.3% annually through 2030.
- Emerging markets represent the primary growth opportunities for traditional pork-based insulin, driven by affordability and existing manufacturing bases.
- Regulatory landscapes vary significantly; companies need tailored strategies to navigate these differences.
- Innovation in delivery methods and long-acting formulations will influence insulin market dynamics, with traditional pork insulin likely to serve niche segments.
FAQs
1. What is the primary advantage of pork-derived insulin?
It is cost-effective and readily available in certain regions, especially where recombinant technology infrastructure is limited.
2. Why is the use of pork insulin declining in developed countries?
Safety concerns, particularly immunogenicity and the availability of recombinant insulin, lead to decreased approvals and use.
3. How do biosimilars impact the market for traditional insulin?
Biosimilars increase competition, lower prices, and expand access, especially in markets with high diabetes prevalence.
4. Are there safety concerns specifically related to pork-derived insulin?
Yes. Animal-derived insulins can stimulate immune responses and vary in potency, prompting regulatory scrutiny.
5. What future innovations could change insulin therapy?
Inhalable insulin, smart insulin delivery systems, and longer-acting formulations are under development, potentially reducing the relevance of animal-sourced insulins.
References
[1] Grand View Research, "Insulin Market Size, Share & Trends Analysis Report," 2023.
[2] International Diabetes Federation, "IDF Diabetes Atlas," 2022.
[Note: All data, dates, and references are current as of 2023. Industry dynamics may shift with regulatory and technological developments.]
